Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Baird cautious on outlook for Gilead's Remdesivir » 08:02
04/07/20
04/07
08:02
04/07/20
08:02
GILD

Gilead

$77.81 /

-0.405 (-0.52%)

Baird analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Gilead price target raised to $86 from $78 at Cantor Fitzgerald » 07:33
04/07/20
04/07
07:33
04/07/20
07:33
GILD

Gilead

$77.81 /

-0.405 (-0.52%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Yesterday
Options
Unusually active option classes on open April 6th » 09:40
04/06/20
04/06
09:40
04/06/20
09:40
MNK

Mallinckrodt

$1.70 /

+ (+0.00%)

, PENN

Penn National

$9.75 /

+ (+0.00%)

, LUV

Southwest

$30.53 /

+ (+0.00%)

, DAL

Delta Air Lines

$22.48 /

+ (+0.00%)

, USO

United States Oil Fund

$5.91 /

+0.005 (+0.08%)

, ACB

Aurora Cannabis

$0.80 /

+ (+0.00%)

, M

Macy's

$4.81 /

+ (+0.00%)

, MSFT

Microsoft

$153.92 /

+ (+0.00%)

, TEVA

Teva

$8.40 /

+ (+0.00%)

, GILD

Gilead

$78.22 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Mallinckrodt (MNK), Penn National (PENN), Southwest (LUV), Delta Air Lines (DAL), United States Oil Fund (USO), Aurora Cannabis (ACB), Macy's (M), Microsoft (MSFT), Teva (TEVA), and Gilead (GILD).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Gilead, Second Genome collaborate on IBD treatments » 06:17
04/06/20
04/06
06:17
04/06/20
06:17
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

Gilead Sciences and…

Gilead Sciences and Second Genome announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead's pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease. Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform to identify novel biomarkers associated with clinical response to Gilead's investigational medicines. This work will harness the latest insights in microbiome science to help inform patient stratification and optimize potential treatments for patients in the future. The platform, in combination with additional discovery and development tools, will also seek to identify new targets and drug candidates relevant to IBD. This will include the identification of up to five novel IBD targets or drug candidates over the next four years, with an option to extend the collaboration for an additional two years. Second Genome will receive $38M in an upfront payment, and up to approximately $300M in success-based preclinical, clinical, regulatory and commercial milestones for each of five target discovery programs as well as low double-digit royalties for any approved products. In addition, it will receive success-based milestones for each validated biomarker delivered under the agreement. Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Sunday
Hot Stocks
Fly Intel: Top five weekend stock stories » 20:09
04/05/20
04/05
20:09
04/05/20
20:09
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

, BA

Boeing

$124.59 /

+1.38 (+1.12%)

, FB

Facebook

$154.19 /

-3.92 (-2.48%)

, TWTR

Twitter

$23.08 /

+0.07 (+0.30%)

, GOOG

Alphabet

$1,097.93 /

-25.87 (-2.30%)

, GOOGL

Alphabet Class A

$1,092.51 /

-24.78 (-2.22%)

, UAL

United Airlines

$22.89 /

-0.53 (-2.26%)

, CMCSA

Comcast

$33.94 /

-0.43 (-1.25%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, T

AT&T

$27.46 /

-1.305 (-4.54%)

, VZ

Verizon

$54.72 /

-0.52 (-0.94%)

, ABT

Abbott

$79.50 /

+0.075 (+0.09%)

, CVX

Chevron

$75.15 /

-1.07 (-1.40%)

, HRL

Hormel Foods

$48.37 /

+0.72 (+1.51%)

, JNJ

Johnson & Johnson

$134.13 /

+1.05 (+0.79%)

, KMB

Kimberly-Clark

$130.02 /

+0.58 (+0.45%)

, MDT

Medtronic

$86.17 /

+0.02 (+0.02%)

, PG

Procter & Gamble

$115.10 /

+0.68 (+0.59%)

, TROW

T. Rowe Price

$95.02 /

-2.13 (-2.19%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Gilead Sciences (GILD) said it is donating 1.5M doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients. In an open letter, Chairman and CEO Daniel O'Day said that the drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms. "Our existing supply, including finished product ready for distribution as well as investigational medicine in the final stages of production, amounts to 1.5 million individual doses. Depending on the optimal duration of treatment, which is something we are studying in clinical trials, this supply could equate to well over 140,000 treatment courses for patients. [...] Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility." 2. Boeing (BA) announced that it is extending the temporary suspension of production operations at all Puget Sound area and Moses Lake sites until further notice. "These actions are being taken in light of the company's continuing focus on the health and safety of employees, current assessment of the spread of COVID-19 in Washington state, the reliability of the supply chain and additional recommendations from government health authorities," the plane maker said in a statement Sunday night. 3. Across the media landscape, advertising is disappearing, one more casualty of the global economic shutdown, and new technology won't be a savior as this is an equal-opportunity problem across print, TV, digital, radio, and outdoor advertising, Eric Savitz wrote in this week's edition of Barron's. Even the most prominent ad buyers lack reasons, and often the means, to buy ads, the author notes, while many of the small and medium-size businesses that buy online ads are struggling to stay solvent. Both Facebook (FB) and Twitter (TWTR) have already warned that they will take a hit from the downturn, and Alphabet's Google (GOOGL) no doubt is seeing the same effects, but so far hasn't discussed the matter, the publication adds. 4. United Airlines (UAL) is cutting nearly 90% of its New York-area flying, as public health officials predicted that the city will reach the peak of its novel coronavirus outbreak in the coming days, The Wall Street Journal's Alison Sider reported. The airline said the reductions set to remain in place for at least three weeks will mean substantially fewer employees will need to show up each day, though workers will continue to receive pay and benefits, the author noted. 5. Comcast (CMCSA), AT&T (T), Verizon (VZ), Abbott Laboratories (ABT), Chevron (CVX), Hormel Foods (HRL), Johnson & Johnson (JNJ), Kimberly-Clark (KMB), Medtronic (MDT), Procter & Gamble (PG), and T. Rowe Price (TROW) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Gilead to donate experimental COVID-19 drug Remdesivir » 15:13
04/05/20
04/05
15:13
04/05/20
15:13
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

Gilead Sciences said it…

Gilead Sciences said it is donating 1.5M doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients. In an open letter, Chairman and CEO Daniel O'Day said that the drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms. "In addition to the expanded access programs, we continue to provide remdesivir on an individual compassionate use basis for children and pregnant women. More than 1,700 patients have now been treated through these programs. [...] As soon as we knew that remdesivir may have potential in treating the novel coronavirus, our teams began to establish a supply chain for large-scale production. Then, as now, there were many unknowns including how long the outbreak would last, at what scale and whether remdesivir is a safe and effective treatment for COVID-19. We made the decision to invest and scale up regardless, because if remdesivir was going to be needed for patients, we had to be ready. In the space of two months, we have significantly increased our available supply of remdesivir using the inventory of active pharmaceutical ingredients we already had on hand. Our existing supply, including finished product ready for distribution as well as investigational medicine in the final stages of production, amounts to 1.5 million individual doses. Depending on the optimal duration of treatment, which is something we are studying in clinical trials, this supply could equate to well over 140,000 treatment courses for patients.[...] Gilead is providing the entirety of this existing supply at no cost, to treat patients with the most severe symptoms of COVID-19. The 1.5 million individual doses are available for compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations. These doses are for treating patients with severe symptoms, through daily intravenous infusions in a hospital setting. Having a potential treatment in our hands comes with significant responsibility. Providing our existing supplies at no charge is the right thing to do, to facilitate access to patients as quickly as possible and in recognition of the public emergency posed by this pandemic." Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Gilead accelerating production of experimental COVID-19 drug, WSJ reports » 14:35
04/05/20
04/05
14:35
04/05/20
14:35
GILD

Gilead

$78.22 /

+1.255 (+1.63%)

Gilead Sciences has…

Gilead Sciences has ramped up production of its experimental coronavirus drug, The Wall Street Journal's Anna Wilde Mathews and Jonathan Rockoff report. The drugmaker said it now has 1.5M individual doses of its drug remdesivir on hand, an amount that could be enough to supply more than 140,000 patients. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Friday
Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 10:25
04/03/20
04/03
10:25
04/03/20
10:25
GILD

Gilead

$78.61 /

+1.65 (+2.14%)

, MYL

Mylan

$14.25 /

+0.34 (+2.44%)

, TEVA

Teva

$8.55 /

+0.43 (+5.30%)

, AMRX

Amneal Pharmaceuticals

$3.02 /

-0.025 (-0.82%)

, ABBV

AbbVie

$74.23 /

-0.895 (-1.19%)

, REGN

Regeneron

$498.01 /

-0.74 (-0.15%)

, ALNY

Alnylam

$102.80 /

-1.58 (-1.51%)

, MRNA

Moderna

$33.88 /

+0.68 (+2.05%)

, INO

Inovio

$7.31 /

-0.19 (-2.53%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Goldman says COVID-19 data by end of month could be next catalyst for Gilead » 07:11
04/03/20
04/03
07:11
04/03/20
07:11
GILD

Gilead

$76.96 /

+4.41 (+6.08%)

Goldman Sachs analyst…

Goldman Sachs analyst Terence Flynn said he expects the first controlled clinical data for Gilead's anti-viral drug remdesivir for the treatment of COVID-19 by the end of the month, noting that this could present the next catalyst for the stock and "possibly a focus for the broader markets as well." Given the pre-clinical data, anecdotal case reports and the broadening clinical program, he thinks the drug will likely demonstrate some degree of activity, but his checks with physicians indicates that much of the focus will be on the ability of the drug to alleviate the burdens on the healthcare system via faster discharge times from the ICU and/or a reduction in the need for a ventilator, Flynn tells investors. While any clinical benefit for remdesivir with acceptable safety could leave it well positioned for potential FDA approval, but he continues to see much of the remdesivir opportunity as priced in, added Flynn, who keeps a Sell rating on Gilead shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 04:55
04/03/20
04/03
04:55
04/03/20
04:55
GILD

Gilead

$76.96 /

+4.41 (+6.08%)

, MYL

Mylan

$13.91 /

-0.34 (-2.39%)

, TEVA

Teva

$8.12 /

-0.35 (-4.13%)

, AMRX

Amneal Pharmaceuticals

$3.05 /

+0.015 (+0.50%)

, ABBV

AbbVie

$75.13 /

+1.655 (+2.25%)

, REGN

Regeneron

$498.75 /

+2.08 (+0.42%)

, ALNY

Alnylam

$104.38 /

-0.13 (-0.12%)

, MRNA

Moderna

$33.20 /

+3.52 (+11.86%)

, INO

Inovio

$7.50 /

-0.19 (-2.47%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.